Clinical Trials Logo

Mumps clinical trials

View clinical trials related to Mumps.

Filter by:

NCT ID: NCT00258726 Terminated - Measles Clinical Trials

Immune Responses to Two Dose Varivax +/- MMR-II

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and varicella virus vaccine (MMR-II). One hundred five healthy children will be enrolled in the study when they are 12 months old. All subjects will be vaccinated at 12 months of age and some subjects will receive a second vaccination at 18 months of age. All subjects will participate for 1 year. This study is a single-site, two-year trial with post-licensure vaccines.

NCT ID: NCT00156559 Completed - Mumps Clinical Trials

MMR and Varicella Vaccine in Premature Infants

Start date: January 2004
Phase: Phase 4
Study type: Observational

This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of varicella and mumps-measles-rubella vaccines in relatively healthy, 12-to-15 month-old children born at <29 weeks gestation, when compared to full-term infants, as measured by the relevant viral serologies.

NCT ID: NCT00138255 Terminated - Measles Clinical Trials

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Start date: June 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term. A group of children who were carried full-term will be matched for age, sex, and race and will be used for comparison.

NCT ID: NCT00127023 Completed - Measles Clinical Trials

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start date: May 2005
Phase: Phase 3
Study type: Interventional

This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

NCT ID: NCT00127010 Completed - Measles Clinical Trials

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

NCT ID: NCT00126997 Completed - Measles Clinical Trials

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start date: May 2005
Phase: Phase 4
Study type: Interventional

This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.

NCT ID: NCT00109343 Completed - Measles Clinical Trials

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes of S. pneumoniae.

NCT ID: NCT00092430 Completed - Measles Clinical Trials

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Start date: September 26, 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with measles, mumps, rubella, and varicella.

NCT ID: NCT00092404 Completed - Measles Clinical Trials

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Start date: December 2001
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.

NCT ID: NCT00092391 Completed - Measles Clinical Trials

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Start date: February 1999
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.